Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma

MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling

(2019) Guang Yan et al.   Cell Communication and Signaling

A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer

(2019) Hye Joung Choi et al.   GYNECOLOGIC ONCOLOGY

Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes

(2018) Jian Shi et al.   Drug Metabolism and Pharmacokinetics

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

(2017) Masao Omata et al.   Hepatology International

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma

(2016) David Friedman et al.   HEPATOLOGY RESEARCH

Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma

(2015) Mi Na Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications

(2015) K. Sartorius et al.   Cancer Epidemiology

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines

(2014) Daniele Baiz   WORLD JOURNAL OF GASTROENTEROLOGY

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

Molecular mechanisms of sorafenib action in liver cancer cells

(2012) Melchiorre Cervello et al.   CELL CYCLE

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2,

(2011) Coral Ho et al.   HEPATOLOGY

Novel molecular therapies in hepatocellular carcinoma

(2011) Sandrine Faivre et al.   LIVER INTERNATIONAL

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

(2011) A.-C. Piguet et al.   MOLECULAR CANCER THERAPEUTICS

Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation

(2010) Hong-rong Fei et al.   CYTOTECHNOLOGY

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathogenesis of hepatocellular carcinoma and molecular therapies

(2009) Beatriz Mínguez et al.   CURRENT OPINION IN GASTROENTEROLOGY

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

(2009) Hung Huynh et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

(2009) Ledu Zhou et al.   MEDICAL ONCOLOGY

Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels

(2008) Daniele Baiz et al.   BIOCHIMIE

Molecular targeted therapies in hepatocellular carcinoma

(2008) Josep M. Llovet et al.   HEPATOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE